Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 11:04 AM ET
Aurinia Pharmaceuticals Inc (AUPH) Financials: Revenue, Profit and Cash Flow
Aurinia Pharmaceuticals reported revenue of $283.06M for the fiscal year ended Dec 31, 2025, up 20.4% from the year before. That year, net income was $287.20M with a net margin of 101.5%, operating cash flow was $135.66M and free cash flow was $135.41M. The quarter ended Sep 30, 2026 had revenue of $83.70M and net income of $31.70M.
Revenue and Margins
The operating margin was 37.1% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $173.00K, a compound annual rate of 127.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $283.06M | +20.4% | 88.5% | 37.1% | 101.5% |
| Dec 2024 | $235.13M | +34.0% | 88.0% | -2.0% | 2.4% |
| Dec 2023 | $175.51M | +31.0% | 91.9% | -52.2% | -44.5% |
| Dec 2022 | $134.03M | +193.9% | 95.8% | -83.2% | -80.7% |
| Dec 2021 | $45.60M | -9.0% | 97.6% | -396.3% | -396.8% |
| Dec 2020 | $50.12M | +15660.4% | 100.0% | -208.1% | -204.9% |
| Dec 2019 | $318.00K | -31.3% | 100.0% | -28598.4% | -27794.0% |
| Dec 2018 | $463.00K | +10.8% | 100.0% | -11930.9% | -11464.1% |
| Dec 2017 | $418.00K | +141.6% | 100.0% | -11212.4% | -16935.9% |
| Dec 2016 | $173.00K | N/A | 0.6% | -14466.5% | -13465.3% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 4894.8% from the year before. In the quarter ended Sep 2026, net income rose 0.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M | $318.00K | $463.00K | $418.00K | $173.00K |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M | $0 | $0 | $0 | $0 | $4.00K |
| Gross profit | $250.39M | $206.88M | $161.37M | $128.37M | $44.51M | $50.12M | $318.00K | $463.00K | $418.00K | $1.00K |
| Research and development | $32.51M | $20.79M | $49.64M | $44.99M | $51.14M | $50.33M | $52.87M | $41.38M | $33.93M | $14.53M |
| Operating income | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M | -$104.29M | -$90.94M | -$55.24M | -$46.87M | -$25.03M |
| Net income | $287.20M | $5.75M | -$78.02M | -$108.18M | -$180.97M | -$102.68M | -$88.39M | -$53.08M | -$70.79M | -$23.30M |
| EBITDA | $114.18M | $2.03M | N/A | -$110.34M | -$177.31M | -$102.92M | -$89.77M | -$53.93M | N/A | -$22.01M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.70M | $83.22M | $77.70M | $77.11M | $73.47M | $70.01M | $62.47M | $59.87M | $67.77M | $57.19M | $50.30M | $45.09M |
| Gross profit | $75.39M | $76.67M | $71.20M | $68.31M | $65.29M | $62.89M | $53.89M | $54.31M | $61.74M | $48.28M | $42.55M | $39.70M |
| Operating income | $35.36M | $46.34M | $41.42M | $33.24M | $29.75M | $20.08M | $21.85M | -$1.67M | $11.75M | -$1.51M | -$13.25M | -$29.67M |
| Net income | $31.70M | $37.41M | $34.35M | $210.79M | $31.55M | $21.51M | $23.34M | $1.43M | $14.35M | $722.00K | -$10.75M | -$26.88M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $17.59M by $62.62M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $751.59M | $550.64M | $548.06M | $470.86M | $543.37M | $463.66M | $324.30M | $145.86M | $189.85M | $57.00M |
| Current assets | $491.97M | $446.60M | $424.80M | $442.54M | $513.32M | $419.43M | $315.14M | $132.85M | $175.25M | $39.73M |
| Cash and equivalents | $80.21M | $83.43M | $48.88M | $94.17M | $231.90M | $272.35M | $306.02M | $117.97M | $165.63M | $39.65M |
| Total liabilities | $170.26M | $173.17M | $170.11M | $65.42M | $64.28M | $55.91M | $25.70M | $33.29M | $24.10M | $21.05M |
| Short-term debt | $17.59M | $15.07M | $15.60M | $936.00K | $1.06M | $788.00K | $6.91M | $118.00K | $4.07M | $2.93M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $21.75M | $11.79M | $9.14M |
| Shareholder equity | $581.33M | $377.48M | $377.95M | $405.44M | $479.09M | $407.75M | $298.60M | $112.58M | $165.74M | $971.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $825.70M | $792.26M | $724.00M | $751.59M | $527.53M | $502.56M | $504.85M | $550.64M | $549.36M | $523.53M | $516.63M | $548.06M |
| Total liabilities | $168.19M | $177.40M | $156.37M | $170.26M | $161.76M | $167.26M | $154.66M | $173.17M | $161.36M | $158.91M | $157.16M | $170.11M |
| Cash and equivalents | $46.15M | $179.83M | $41.01M | $80.21M | $73.19M | $53.00M | $66.43M | $83.43M | $37.14M | $33.41M | $64.46M | $48.88M |
| Shareholder equity | $657.52M | $614.86M | $567.63M | $581.33M | $365.77M | $335.30M | $350.19M | $377.48M | $388.00M | $364.62M | $359.48M | $377.95M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.8% of operating cash flow. Share repurchases came to 72.5% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $135.66M | $44.39M | -$33.46M | -$79.53M | -$157.69M | -$69.86M | -$63.59M | -$51.61M | -$41.17M | -$20.76M |
| Capital expenditures | $252.00K | $281.00K | $718.00K | $292.00K | $1.50M | $7.34M | $85.00K | $74.00K | $25.00K | $25.00K |
| Free cash flow | $135.41M | $44.11M | -$34.18M | -$79.82M | -$159.19M | -$77.20M | -$63.67M | -$51.69M | -$41.19M | -$20.78M |
| Share repurchases | $98.16M | $40.24M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$32.77M | $39.26M | -$6.71M | -$60.63M | -$103.87M | -$158.19M | $7.78M | -$65.00K | -$8.00M | $31.15M |
| Financing cash flow | -$106.11M | -$49.09M | -$5.13M | $2.43M | $221.11M | $194.38M | $243.85M | $4.01M | $175.15M | $33.96M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $46.37M | $52.57M | $32.56M | $45.67M | $44.45M | $44.24M | $1.30M | $30.11M | $17.03M | $15.84M | -$18.60M | $14.31M |
| Capital expenditures | $24.00K | N/A | $39.00K | $72.00K | $65.00K | $98.00K | $17.00K | $56.00K | $85.00K | $128.00K | $12.00K | $299.00K |
| Free cash flow | $46.34M | N/A | $32.52M | $45.60M | $44.38M | $44.14M | $1.28M | $30.06M | $16.94M | $15.71M | -$18.61M | $14.01M |
Frequently Asked Questions About AUPH
What is Aurinia Pharmaceuticals' annual revenue?
Aurinia Pharmaceuticals reported revenue of $283.06M for the fiscal year ended Dec 31, 2025.
How fast is Aurinia Pharmaceuticals' revenue growing?
Revenue was up 20.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 28.3%.
Is Aurinia Pharmaceuticals profitable?
Yes. Aurinia Pharmaceuticals reported net income of $287.20M for the fiscal year ended Dec 31, 2025, with a net margin of 101.5%.
How much free cash flow does AUPH generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $135.66M minus capital expenditures of $252.00K produced free cash flow of $135.41M.
How much debt does Aurinia Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $17.59M and cash and equivalents of $80.21M.
AUPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors